SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Phil Cressman who wrote (10491)10/31/1997 11:31:00 AM
From: tdinovo  Read Replies (1) | Respond to of 32384
 
Phil,
I have a somewhat different take on an acquisition as well. It seems to me what Ligand needs most now is a revenue stream to begin offsetting the increased cash burn that will evolve as ALRI becomes history. If I were Robinson, I'd be looking for a generic house that addressed at least some of the key markets that I expected to address withmy current stable of compounds. It seems to me that the last thing Ligand needs right now is another compound to develop.

In addition to the revenue, you get a sales force and a market presence that otherwise you would have to build yourself. I would also try to do a stock-for-stock deal, if at all possible.

I know this leaves the issue of which LLY drug they specify up in the air. But I really don't see why the two putative actions should be connected. Anyone any thoughts?
Ted



To: Phil Cressman who wrote (10491)10/31/1997 2:37:00 PM
From: Andrew H  Respond to of 32384
 
Question is, is just how much is the DAB protein worth? If it really works as well as it seems with a significant % of psoriasis patients, it could be worth a lot. However, if it is running out of cash, LGND might be able to get it for a song and dance as well as corner the CTCL market, which is not terribly lucrative. But there is an interesting technology behind the drug which might be worth something as well.

Depends just how much milk that cow has to give. (:>)